2021
DOI: 10.18632/aging.202882
|View full text |Cite
|
Sign up to set email alerts
|

Transcriptome integration analysis and specific diagnosis model construction for Hodgkin's lymphoma, diffuse large B-cell lymphoma, and mantle cell lymphoma

Abstract: Transcriptome differences between Hodgkin's lymphoma (HL), diffuse large B-cell lymphoma (DLBCL), and mantle cell lymphoma (MCL), which are all derived from B cell, remained unclear. This study aimed to construct lymphoma-specific diagnostic models by screening lymphoma marker genes. Transcriptome data of HL, DLBCL, and MCL were obtained from public databases. Lymphoma marker genes were screened by comparing cases and controls as well as the intergroup differences among lymphomas. A total of 9 HL marker genes,… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
4
0

Year Published

2022
2022
2022
2022

Publication Types

Select...
2

Relationship

1
1

Authors

Journals

citations
Cited by 2 publications
(4 citation statements)
references
References 72 publications
0
4
0
Order By: Relevance
“…The details of lymphoma datasets see our previous publication [ 19 ]. This study collected 240 HL samples, 891 DLBCL samples, 216 MCL samples, and 64 health samples.…”
Section: Resultsmentioning
confidence: 99%
See 2 more Smart Citations
“…The details of lymphoma datasets see our previous publication [ 19 ]. This study collected 240 HL samples, 891 DLBCL samples, 216 MCL samples, and 64 health samples.…”
Section: Resultsmentioning
confidence: 99%
“…Transcriptome datasets of HL, DLBCL, and MCL were downloaded from NCBI-GEO ( https://www.ncbi.nlm.nih.gov/geo/ ). For detailed data inclusion and exclusion criteria, please refer to our previous work [ 19 ]. Briefly, this study collected 14 lymphoma datasets including 240 HL samples, 891 DLBCL samples, 216 MCL samples, and 64 healthy samples.…”
Section: Methodsmentioning
confidence: 99%
See 1 more Smart Citation
“…However, patients with SAP may develop immunosuppression, resulting in pancreatic necrosis and secondary infection [23,24]. IGKV4-1 is involved in the protection of acute rejection and considered an effective biomarker for the early identification of mantle cell lymphoma [25,26]. IGHG3, which is also involved in acute rejection [27], may contribute to platelet activation during ischemic stroke, and it is expected to be a potential target for the treatment of the early phase of stroke [28].…”
Section: Discussionmentioning
confidence: 99%